ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (NASDAQ: IMGN) will host a conference call on November 4, 2022, at 8:00 a.m. ET to discuss its third-quarter 2022 operating results and provide a brief business update. The call will be accessible by phone with a registration link available. Investors can also access details through the company’s website. ImmunoGen focuses on developing next-generation antibody-drug conjugates (ADCs) to enhance cancer treatment outcomes, aiming to disrupt cancer progression and improve patient quality of life.

Positive

• ImmunoGen is actively engaging with investors through a conference call to discuss Q3 2022 results.
• The focus on developing next-generation ADCs positions ImmunoGen well in the cancer treatment market.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its third quarter 2022 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005187/en/

INVESTOR RELATIONS CONTACT

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com



MEDIA CONTACTS

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com



OR



FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

When is ImmunoGen's conference call for Q3 2022 results?

ImmunoGen's conference call for Q3 2022 results is scheduled for November 4, 2022, at 8:00 a.m. ET.

How can I access ImmunoGen's conference call?

You can access ImmunoGen's conference call by registering through the provided link in their press release.

What is the focus of ImmunoGen's development efforts?

ImmunoGen is focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.

What is the stock symbol for ImmunoGen?

The stock symbol for ImmunoGen is IMGN.